NEWS
Experimental drug increases metabolic rate: study
POSTED 09 Mar 2015 . BY Helen Andrews
While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome Credit: Shutterstock / Andresr
An experimental drug has been found to speed up metabolism and burn off fat cells, according to a study conducted on hundreds of mice by the Houston Methodist Research Institute, US.

Dubbed ‘GC-1’, the drug works by activating the receptors for thyroid hormone, which play a role in regulating the metabolism – the body’s conversion of food into energy.

“CG-1 dramatically increases the metabolic rate, essentially converting white fat, which stores excess calories and is associated with obesity and metabolic disease, into a fat like calorie-burning brown fat,” said the study’s author Kevin Phillips PhD.

Until several years ago, scientists thought that only animals and human infants had energy-burning “good” brown fat.

“It is now clear,” said Phillips, “that human adults do have brown fat, but it appears to lose its calorie-burning capacity over time.”

White adipose tissue, or fat, becomes a “metabolic villain” when the body has too much of it, according to Phillips. People with more brown fat have a reduced risk of obesity and diabetes, thus researchers are now working on ways to convert white fat into brown fat.

Phillips and other researchers tested the drug on hundreds of mice, with partial funding from the National Institutes of Health, according to ScienceDaily. Both genetically obese mice and those with diet-induced obesity received GC-1 treatment daily.

The genetically obese mice lost weight and more than 50 per cent of their fat mass in approximately two weeks, according to Phillips. The treated mice also showed anti-diabetic effects, such as a six-fold improvement or better insulin sensitivity – how well the body clears glucose from the bloodstream. Mice with diet-induced obesity experienced similar improvements, said Phillips.

“Our data demonstrate that GC-1 is a novel fat-browning agent that may have a use in the treatment of obesity and metabolic disease,” added Phillips.

While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome. Phillips said, however, that the doses of sobetirome used in cholesterol-lowering trials are much lower than what would be needed for weight loss.

A recent study found that obese people have fewer ‘pleasure receptors’ in their brains, which could explain their need to overeat.
RELATED STORIES
  Obese people's brains have fewer ‘pleasure receptors’: study


People with obesity have a significantly lower number of neurotransmitters dedicated to generating pleasurable sensations than people of a normal weight, according to a study, which could explain why they have difficulty restraining their eating.
  Cut sugar consumption to less than 10 per cent of daily energy intake: WHO


The World Health Organisation (WHO) has issued new guidelines on sugar consumption that say adults and children from most countries in the world should roughly halve the amount of sugar they eat to lower the risk of obesity and tooth decay.
  Childhood obesity campaign combines physical activity with altruism


Technogym is urging health clubs around the world to get their members moving during March with the added incentive of helping to tackle childhood obesity.
  Tackle obesity or risk losing benefits, says PM


David Cameron has outlined plans for tough new measures that could see obese people on sickness benefits have their income cut if they refuse treatment for the condition.
 


CONTACT US

Leisure Media
Tel: +44 (0)1462 431385

©Cybertrek 2026

ABOUT LEISURE MEDIA
LEISURE MEDIA MAGAZINES
LEISURE MEDIA HANDBOOKS
LEISURE MEDIA WEBSITES
LEISURE MEDIA PRODUCT SEARCH
PRINT SUBSCRIPTIONS
FREE DIGITAL SUBSCRIPTIONS
 
Leisure Management - Experimental drug increases metabolic rate: study...
08 Jun 2026 Leisure Management: daily news and jobs
 
 
HOME
JOBS
NEWS
FEATURES
PRODUCTS
FREE DIGITAL SUBSCRIPTION
PRINT SUBSCRIPTION
ADVERTISE
CONTACT US
Sign up for FREE ezine
Latest news

09 Mar 2015

Experimental drug increases metabolic rate: study
BY Helen Andrews

While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome

While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome
photo: Shutterstock / Andresr

An experimental drug has been found to speed up metabolism and burn off fat cells, according to a study conducted on hundreds of mice by the Houston Methodist Research Institute, US.

Dubbed ‘GC-1’, the drug works by activating the receptors for thyroid hormone, which play a role in regulating the metabolism – the body’s conversion of food into energy.

“CG-1 dramatically increases the metabolic rate, essentially converting white fat, which stores excess calories and is associated with obesity and metabolic disease, into a fat like calorie-burning brown fat,” said the study’s author Kevin Phillips PhD.

Until several years ago, scientists thought that only animals and human infants had energy-burning “good” brown fat.

“It is now clear,” said Phillips, “that human adults do have brown fat, but it appears to lose its calorie-burning capacity over time.”

White adipose tissue, or fat, becomes a “metabolic villain” when the body has too much of it, according to Phillips. People with more brown fat have a reduced risk of obesity and diabetes, thus researchers are now working on ways to convert white fat into brown fat.

Phillips and other researchers tested the drug on hundreds of mice, with partial funding from the National Institutes of Health, according to ScienceDaily. Both genetically obese mice and those with diet-induced obesity received GC-1 treatment daily.

The genetically obese mice lost weight and more than 50 per cent of their fat mass in approximately two weeks, according to Phillips. The treated mice also showed anti-diabetic effects, such as a six-fold improvement or better insulin sensitivity – how well the body clears glucose from the bloodstream. Mice with diet-induced obesity experienced similar improvements, said Phillips.

“Our data demonstrate that GC-1 is a novel fat-browning agent that may have a use in the treatment of obesity and metabolic disease,” added Phillips.

While the drug has not yet undergone testing for weight loss in humans, GC-1 is being tested in clinical trials for lowering cholesterol under the name sobetirome. Phillips said, however, that the doses of sobetirome used in cholesterol-lowering trials are much lower than what would be needed for weight loss.

A recent study found that obese people have fewer ‘pleasure receptors’ in their brains, which could explain their need to overeat.



Connect with
Leisure Management
Magazine:
View issue contents
Sign up:
Instant Alerts/zines

Print edition
 

News headlines
Longevitix launches AI-powered platform to deliver longevity medicine at scale
Longevitix launches AI-powered platform to deliver longevity medicine at scale   08 Jun 2026

Longevitix, a clinical platform for preventive and longevity medicine, has launched its AI-powered intelligence system to help physicians deliver .... more>>

Orangetheory set for Italian expansion and Technogym tie-up
Orangetheory set for Italian expansion and Technogym tie-up   08 Jun 2026

Purpose Brands has announced its entry into the Italian market, having sold the franchise rights for four Orangetheory Fitness studios to Icon .... more>>

Atmantan Wellness Centre announces new wellness destination in Hyderabad
Atmantan Wellness Centre announces new wellness destination in Hyderabad   08 Jun 2026

Atmantan Wellness Centre, an integrative wellness destination in Mulshi, near Pune in India, is expanding its portfolio by adding a new centre in .... more>>

Fitness First adds red light therapy to relaxation classes
Fitness First adds red light therapy to relaxation classes   08 Jun 2026

Fitness First UK is integrating red light therapy into its yoga and Pilates classes through a partnership with Bon Charge.

....
more>>
The Retreat Costa Rica debuts Vida Mía Longevity Centre
The Retreat Costa Rica debuts Vida Mía Longevity Centre   07 Jun 2026

Luxury wellness resort, The Retreat Costa Rica, has introduced its Vida Mía Longevity Centre at the property’s Vida Mía Healing Centre and .... more>>

Almost half of spa survey respondents are unaware cancer is a disability and not adapting treatments is discrimination
Almost half of spa survey respondents are unaware cancer is a disability and not adapting treatments is discrimination   05 Jun 2026

A recent survey by the UK Spa Association (UKSA) into the industry’s approach to cancer care has revealed that almost half of participating .... more>>

Company profile


Hydrafacial

Founded in 1997, Hydrafacial has grown to become one of the world’s leading skin health brands.

View full profile>>

Catalogue gallery


Featured Supplier

Endospheres' new protocols are designed to meet real client needs

Endospheres' new protocols are designed to meet real client needs

Spa professionals see it every day: clients are arriving with more complex expectations. More>>




in this issue

• Virgin gets right to wipe out rent arrears
• Fitness industry mourns passing of Jan Spaticchia
• STA offers mindfulness resources



Latest jobs

Jobs Search



Membership Advisor
Salary: Competitive salary plus commission & benefits
Location: Market Rasen
Company: Everyone Active
Customer Service Advisor
Salary: Competitive
Location: Market Rasen
Company: Everyone Active
GP Exercise Referral Instructor
Salary: £33,000pa + benefits
Location: Harrow
Company: Everyone Active
Diary dates
Powered by leisurediary.com

09-11 Jun 2026

World Sauna Forum 2026

Savutuvan Apaja, Haapaniemi, Finland







Published by Leisure Media Tel: +44 (0)1462 431385 | Contact us | About us | © Cybertrek Ltd